Maurer Florian P, Christner Martin, Hentschke Moritz, Rohde Holger
Institute of Medical Microbiology, Virology and Hygiene.
Antibiotic Stewardship Team, University Medical Centre Hamburg-Eppendorf, Hamburg.
Infect Dis Rep. 2017 Mar 30;9(1):6839. doi: 10.4081/idr.2017.6839.
Early availability of information on bacterial pathogens and their antimicrobial susceptibility is of key importance for the management of infectious diseases patients. Currently, using traditional approaches, it usually takes at least 48 hours for identification and susceptibility testing of bacterial pathogens. Therefore, the slowness of diagnostic procedures drives prolongation of empiric, potentially inappropriate, antibacterial therapies. Over the last couple of years, the improvement of available techniques ( for susceptibility testing, DNA amplification assays), and introduction of novel technologies ( MALDI-TOF) has fundamentally changed approaches towards pathogen identification and characterization. Importantly, these techniques offer increased diagnostic resolution while at the same time shorten the time-to-result, and are thus of obvious importance for antimicrobial stewardship. In this review, we will discuss recent advances in medical microbiology with special emphasis on the impact of novel techniques on antimicrobial stewardship programs.
尽早获得有关细菌病原体及其抗菌药敏性的信息对于传染病患者的管理至关重要。目前，采用传统方法，细菌病原体的鉴定和药敏试验通常至少需要48小时。因此，诊断程序的缓慢导致经验性、可能不恰当的抗菌治疗时间延长。在过去几年中，现有技术（用于药敏试验、DNA扩增检测）的改进以及新技术（基质辅助激光解吸电离飞行时间质谱）的引入从根本上改变了病原体鉴定和特征描述的方法。重要的是，这些技术提高了诊断分辨率，同时缩短了出结果的时间，因此对抗菌药物管理具有明显的重要性。在本综述中，我们将讨论医学微生物学的最新进展，特别强调新技术对抗菌药物管理计划的影响。
